Skip to content

Safety and Efficacy of Esketamine Versus Remifentanil as Adjuncts to Propofol Sedation in Children Undergoing Hematologic-Oncologic Procedures: A Randomized Crossover Controlled Trial

Safety and Efficacy of Esketamine Versus Remifentanil as Adjuncts to Propofol Sedation in Children Undergoing Hematologic-Oncologic Procedures: A Randomized Crossover Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098533
Enrollment
Unknown
Registered
2025-03-10
Start date
2026-01-27
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

AB sequence:During the first invasive procedure under sedation, sedation is induced with propofol at 3 mg/kg, followed by esketamine administration at 0.5mg/kg. When the patients move or show signs of
BA sequence:During the first invasive procedure under sedation, sedation is induced with propofol at 3 mg/kg, followed by remifentanil administration at 1µg/kg. When the patients move or show signs of

Sponsors

Children's Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosed with acute lymphoblastic leukemia, acute myelogenous leukemia or meningeal leukemia following the initial bone marrow biopsy according to the WHO diagnostic criteria; 2.Children aged 6-12 years at trial entry; 3.Body mass index (BMI) 18–30kg/m^2; 4.American Society of Anesthesiologists (ASA) physical status II or III; 5.Patients are anticipated to undergo at least two similar invasive procedures, specifically bone marrow aspiration and lumbar puncture, during chemotherapy. A minimum washout period of five days is required between these procedures; 6.Being able to precisely articulate feelings and experiences.

Exclusion criteria

Exclusion criteria: 1.Children with severe cardiorespiratory conditions or other poorly controlled medical conditions that, in the investigator's professional judgment, would compromise the integrity of the trial; 2.Allergy or hypersensitivity to any of the study medication; 3.The child may experience nausea, vomiting and pain as a result of the illness itself or adverse reactions to medication; 4. History of psychological problems.

Design outcomes

Primary

MeasureTime frame
Incidence of desaturation events during the procedures;

Secondary

MeasureTime frame
The interruption rate of the procedure;Total dose of propofol;The number of times esketamine or remifentanil is added;Recovery time ;Distress behavior;A composite of sedation related adverse events after the procedures;Patient satisfaction;Operator satisfaction;Anesthetist satisfaction;

Countries

China

Contacts

Public ContactWang Qian

Children's Hospital of Soochow University

q_wang0302@suda.edu.cn+86 138 1206 0644

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 21, 2026